KURA•benzinga•
Kura Oncology And Kyowa Kirin Announce Phase 2 KOMET-001 Trial Results For Once-Daily Oral Menin Inhibitor Ziftomenib In Relapsed/Refractory NPM1-Mutated AML Showing 23% CR/CRh Rate, Durable MRD-Negative Responses Across Key Subgroups, Favorable Safety Wi
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga